Published in Cancer Weekly, February 15th, 2005
The phase 1b component is an open label dose escalation study that is being conducted at two leading clinical research sites within the United States, enrolling patients with advanced cancer, some of whom may have previously received gemcitabine.
ArQule anticipates that this component will be followed by a phase II study exploring the use of ARQ 501 and gemcitabine in patients with advanced cancer. The phase Ib/II study is being conducted by ArQule as part of its strategic alliance with Roche to explore...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.